Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...
Yahoo Finance8d
Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions
Neurocrine Biosciences announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, though the ...
Yahoo Finance10d
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability ...
Morningstar3d
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18 ...
Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at ...
Yahoo Finance17d
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. (PRNewsfoto ...
Benzinga.com21d
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below offers a condensed view of their recent ratings ...
The Victoria Advocate22d
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...
Hosted on MSN28d
Neurocrine Biosciences CFO sells shares worth $298,922
Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a company currently valued at $11.4 billion with strong financial health according to InvestingPro analysis ...
Stockhouse22d
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...